Skip to main content

Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial

Supportive Care in Cancer volume 30, pages 9833–9840 (2022)Cite this article

Abstract

Purpose

In many cases, pleurodesis is the only treatment available for the treatment of malignant pleural effusion (MPE), and in the case of excessive daily pleural effusion, its therapeutic effect may be reduced. In this study, we intended to investigate the therapeutic effects and safety of octreotide in patients with MPE undergoing pleurodesis with talc powder.

Methods

This study was a single-center, placebo-controlled, and triple-blind, randomized trial designed to investigate the therapeutic effects and safety of octreotide in patients with MPE in Tehran, Iran, from March 2020 to March 2021. Patients with MPE were randomly divided into two parallel groups, one receiving subcutaneous octreotide (3 doses of 50 µg/day) and the other receiving placebo before and after pleurodesis with talc powder. The patients were followed up with a chest X-ray 1 week, 1 month, and 3 months later. The primary outcome measures of this study were the amount of discharge from the chest tube before and after pleurodesis and the length of hospital stay. Treatment failure, relapse, pleural effusion analysis, and side effects were considered the secondary outcome measures of the study.

Results

A total of 46 patients (23 in the octreotide group and 23 in the placebo group) with MPE was included in this study. Our findings demonstrated that adjunctive treatment with subcutaneous octreotide increases the efficacy of pleurodesis with talc powder. We showed that compared to the placebo group, patients in the octreotide group have significantly decreased production of pleural effusion both before (p = 0.009) and after (p = 0.002) pleurodesis. Octreotide treatment led to a decreased hospital stay (p = 0.004 before pleurodesis and p = 0.001 after pleurodesis) and reduced treatment failure (p = 0.022). However, octreotide did not decrease the relapse at 1-week, 1-month, and 3-month follow-ups. Moreover, octreotide did not affect pleural effusion parameters compared to placebo. Ultimately, our results also showed that treatment with octreotide was safe and did not have significant side effects.

Conclusion

Our findings demonstrated that adjunctive treatment with subcutaneous octreotide increases the efficacy of pleurodesis with talc powder without any significant side effects. Future studies with a larger sample size and longer follow-up time can confirm the results of this study and also determine the appropriate dose of octreotide for the treatment of MPE.

Trial registration

Iranian Registry of Clinical Trials, IRCT20210915052492N1. Registered 11 October 2021 – Retrospectively registered, https://www.irct.ir/trial/58776.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.

References

  1. Beaudoin S, Gonzalez A (2018) Evaluation of the patient with pleural effusion. CMAJ 190(10):E291–E295

  2. Bender B, Murthy V, Chamberlain RS (2016) The changing management of chylothorax in the modern era. Eur J Cardiothorac Surg 49(1):18–24

  3. Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M et al (2019) ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg 55(1):116–132

  4. Caverly L, Rausch CM, da Cruz E, Kaufman J (2010) Octreotide treatment of chylothorax in pediatric patients following cardiothoracic surgery. Congenit Heart Dis 5:573–578

    Article  PubMed  Google Scholar 

  5. Chen Y, Mathy NW, Lu H (2018) The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer. Mol Med Rep 17(6):8019–8030

  6. Helin RD, Angeles STV, Bhat R (2006) Octreotide therapy for chylothorax in infants and children: a brief review. Pediatr Crit Care Med 7(6):576–579

  7. Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC (2012) A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology 82:315–320

    Article  CAS  PubMed  Google Scholar 

  8. Kambayashi T, Nakatsukasa H, Motoi M, Kato N (2012) Investigation of the utility of octreotide for malignant ascites. Palliat Care Res 7(1):314–316

  9. Kilic D, Sahin E, Gulcan O, Bolat B, Turkoz R, Hatipoglu A (2005) Octreotide for treating chylothorax after cardiac surgery. Tex Heart Inst J 32(3):437–439

  10. Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I (2017) Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res 9(10):229–241

  11. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT (2016) Malignant pleural effusion: from bench to bedside. Eur Respir Rev 25(140):189–198

  12. Roehr CC, Jung A, Proquitté H, Blankenstein O, Hammer H, Lakhoo K, Wauer RR (2006) Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med 32:650–657

    Article  CAS  PubMed  Google Scholar 

  13. Shah D (1992) Sinn JK (2012) Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series Acta paediatrica (Oslo. Norway 101:e151-155

    Google Scholar 

  14. Sharkey AJ, Rao JN (2012) The successful use of octreotide in the treatment of traumatic chylothorax. Tex Heart Inst J 39(3):428

  15. Stathopoulos GT, Kalomenidis I (2012) Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 186:487–492

    Article  PubMed  Google Scholar 

  16. Stephens J, Carpiuc KT, Botteman M (2010) The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. Int J Gen Med 3:31–36

    PubMed  PubMed Central  Google Scholar 

  17. Yalcin NG, Choong CK, Eizenberg N (2013) Anatomy and pathophysiology of the pleura and pleural space. Thorac Cardiovasc Surg 23(1–10):v

    Google Scholar 

  18. Yeh J, Brown ER, Kellogg KA, Donohue JE, Yu S, Gaies MG, Fifer CG, Hirsch JC, Aiyagari R (2013) Utility of a clinical practice guideline in treatment of chylothorax in the postoperative congenital heart patient. Ann Thorac Surg 96:930–936

    Article  PubMed  Google Scholar 

  19. Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, Chen C, Cao Y (2017) Effects of somatostatin/octreotide treatment in neonates with congenital chylothorax. Medicine (Baltimore) 96:e7594–e7594

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Reza Ershadi and Matin Vahedi have contributed equally work.

Authors and Affiliations

  1. Department of Thoracic Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

    Reza Ershadi, Matin Vahedi, Javad Sarbaz Zadeh & Shahab Rafieian

  2. Advanced Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Hossein Kazemi Zadeh

  3. Department of Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Farhad Fathi

  4. Department of Surgery, Birjand University of Medical Sciences, Birjand, Iran

    Hossein Ebrahimpour

Authors
  1. Reza Ershadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matin Vahedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Kazemi Zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farhad Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hossein Ebrahimpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Javad Sarbaz Zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shahab Rafieian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RE: conception and design of the study, drafting the article, and approval of the final version of manuscript; MV: acquisition of data, conception and design of the study, drafting the article, and approval of the final version of manuscript; HKZ: acquisition of data, critical revise, and approval of the final version of manuscript; FF: acquisition of data, critical revise, and approval of the final version of manuscript; HE: acquisition of data, critical revise, and approval of the final version of manuscript; JSZ: acquisition of data, critical revise, and approval of the final version of manuscript; SR: conception and design of the study, drafting the article, analysis and interpretation of data, and approval of the final version of manuscript.

Corresponding author

Correspondence to Shahab Rafieian.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethics committee of Tehran University of Medical Sciences approved the study with the number IR.TUMS.IKCH.REC.1399.498.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Conflict of interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 32 KB)

Supplementary file2 (DOCX 22 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ershadi, R., Vahedi, M., Zadeh, H.K. et al. Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: a placebo-controlled, triple-blind, randomized trial. Support Care Cancer 30, 9833–9840 (2022). https://doi.org/10.1007/s00520-022-07440-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-07440-5

Keywords

  • Malignant pleural effusion
  • Octreotide
  • Pleurodesis